Inflammation has accompanied human beings since the emergence of wounds and infections. In the past decades, numerous efforts have been undertaken to explore the potential role of inflammation in cancer, from tumor development, invasion, and metastasis to the resistance of tumors to treatment. Inflamma...
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Differ. 21, 491–502 (2014). Article CAS PubMed Google Scholar De Blasio, A. et al. Loss of MCL1 function sensitizes the MDA-MB-231 breast cancer cells to rh-TRAIL by ...
Various strategies to target Myc. Inhibitors of BRD4, CDK7, and CDK9 inhibitMYCexpression at the transcriptional level. Inhibition of the PI3K/AKT/mTOR pathway blocksMYCtranslation, whereas USP7, AURKA, and PLK1 inhibitors destabilize Myc at the posttranslational level. 10058-F4 and Omomyc function...
Phosphorylation of MCL-1 residues in the PEST domain by protein kinases, such as CDK1/2, GSK-3, JNK, and ERK, also affects the stability of MCL-1 [13, 30, 31]. MCL-1 as a target for cancer therapy MCL-1 is a key survival factor for many cell types, allowing it to strictly ...
Recently, progress has been made in the development of therapeutics against KRASG12C mutation,3, 4, 5, 6, 7 which is present in ~15% of lung adenocarcinoma and 0%–8% of other cancers (Table 1).8,9 Results from early-stage clinical trials indicate that many cancer patients in this ...
Thus, the inhibition of c-Myc has promise as a therapeutic strategy for human cancer [5, 6]. Here we review structural and functional features of c-Myc and highlight to discuss possible small molecule modulators of c-Myc as promising anti-cancer therapeutics....
Targeting Notch degradation system provides promise for breast cancer therapeutics. Crit. Rev. Oncol. Hematol. 2016, 104, 21–29. [CrossRef] [PubMed] 101. Walf-Vorderwülbecke, V.; Pearce, K.; Brooks, T.; Hubank, M.; van den Heuvel-Eibrink, M.M.; Zwaan, C.M.; Adams, S.; ...
(LNP) decorated with anti-PD-L1 antibodies on its surface [36]. This platform (αPD-L1-LNP) was further encapsulated with a cyclin-dependent kinase (CDK) inhibitor dinaciclib to induce the depletion of TAMCs and impair their immunosuppressive roles. Notably, the targeting efficiency of αPD-...
Therefore CDK inhibitors and related transcription factors have long been viewed as potential targets for anticancer therapeutics. Despite years of research and attempts directed at inhibiting cell cycle kinases or cell cycle regulating transcription factors, most of these approaches have not been ...
Targeting cell-cycle machinery represents an attractive anti-cancer therapeutic strategy, and chemical inhibitorsof cyclin-CDK kinases are in clinical trials. 靶向细胞周期机制是一种有吸引力的抗癌治疗策略,cyclinc - cdk激酶的化学抑制剂正在临床试验中。